[Interest in treatment with subconjunctival clindamycin in toxoplasmic retinochoroiditis].
To demonstrate advantages of using subconjunctival injections of clindamycin in the treatment of toxoplasmic retinchoroiditis. A prospective study was conducted in 13 patients with unilateral toxoplasmic retinochoroiditis. All cases were treated with subconjunctival injections of clindamycin in association with general corticosteroïds. Mean follow-up was 7.6 months. Subjective improvement of the visual acuity was obtained in 67% during the first week. Cicatrization was obtained in 1.4 months on average. Recurrences were developed in 15% of cases. Clindamycin did not produce any general side effects, however a conjunctival inflammation and keratitis were observed in one case caused by an error in concentration of clindamycin. Subconjunctival injections of clindamycin provide an interesting alternative in the choice of antitoxoplasmic ocular therapy.